Abstract CT230: STRIDE regimen of tremelimumab and durvalumab as non-operative management strategy of microsatellite instability-high (MSI-H) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC): Final results of the cohort 2 of INFINITY study by GONO GI - Alberto Giovanni Leone; Alessandra Raimondi; Paolo Manca; Sabina Murgioni; Giovanni G. Cardellino; Alessandro Bittoni; Antonia Strippoli; Maria Bencivenga; Federica Palermo; Floriana Nappo; Silvio K. Garattini; Thereasa Rich; et al. (Cancer Research, 2026)